Giardia duodenalis Assemblages in Dogs and Cats: Zoonotic Genotyping and Clinical Management

Etiology and Taxonomic Context

Giardia duodenalis (syn. G. lamblia, G. intestinalis) is a flagellated protozoan parasite of the order Diplomonadida. The species complex comprises eight genetically distinct assemblages (A through H) that exhibit varying degrees of host specificity. Assemblages A and B are considered zoonotic, infecting humans, companion animals, livestock, and wildlife. Assemblages C and D are predominantly found in canids, while assemblage F is primarily associated with felids. Assemblages E, G, and H are restricted to hoofed livestock, rodents, and marine mammals, respectively [1, 2, 3].

The genetic differentiation among assemblages is based on sequence polymorphisms at multiple loci, including the beta-giardin (bg), glutamate dehydrogenase (gdh), triose phosphate isomerase (tpi), and small subunit ribosomal RNA (SSU rRNA) genes. Multilocus genotyping (MLG) provides the highest resolution for assemblage discrimination and is considered the reference standard for molecular epidemiological studies [1, 4].

Lifecycle and Transmission

Giardia duodenalis has a direct lifecycle consisting of two morphologically distinct stages: the trophozoite and the cyst. Trophozoites are pear-shaped, binucleate, flagellated organisms that colonize the proximal small intestine, attaching to enterocytes via a ventral adhesive disc. Trophozoites replicate by longitudinal binary fission. Encystation occurs as organisms transit toward the colon, triggered by bile salts, alkaline pH, and cholesterol deprivation. Mature cysts are shed intermittently in feces and are immediately infectious upon excretion.

Transmission occurs via the fecal-oral route through ingestion of cysts from contaminated water, food, fomites, or direct contact with infected animals. The infectious dose for dogs and cats is low, estimated at fewer than 10 cysts. Cysts are environmentally robust, surviving for weeks to months in cool, moist conditions and resisting standard chlorination at municipal water treatment concentrations [5, 6].

Epidemiology and Assemblage Distribution

Global Prevalence in Dogs and Cats

Prevalence rates of G. duodenalis in dogs and cats vary widely by geographic region, diagnostic method, and population demographics. In shelter populations, prevalence is consistently higher than in owned pets due to crowding, stress, and poor sanitation. A systematic review and meta-analysis of canine giardiasis in China reported a pooled prevalence of 12.8% (95% CI: 10.2-15.6%) based on 30 studies [7]. Studies from Europe, the Middle East, and the Americas report comparable ranges [5, 8, 9, 10, 11, 12, 13].

Assemblage Distribution in Dogs

In dogs, assemblages C and D are the most frequently identified, consistent with their canid-adapted nature. However, zoonotic assemblages A and B are also detected at variable frequencies. A study of shelter dogs in South Korea found that 68.4% of positive samples harbored assemblage C, 21.1% assemblage D, and 10.5% assemblage A [8]. In Poland, assemblage C predominated in dogs (52.9%), followed by assemblage D (29.4%) and assemblage A (17.6%) [5]. Studies from Iran, Turkey, and Brazil have similarly reported a predominance of canid-adapted assemblages with a notable minority of zoonotic genotypes [14, 9, 15, 16].

Assemblage Distribution in Cats

Feline infections are most commonly attributed to assemblage F, the felid-adapted genotype. Zoonotic assemblages A and B are also reported in cats, though at lower frequencies than in dogs. A study from Bangladesh detected assemblage A in 33.3% of positive feline samples and assemblage F in 66.7% [3]. In Egypt, assemblage A was the sole genotype identified in cats [17]. A comprehensive review of feline giardiasis noted that assemblage F is the dominant genotype in most geographic regions, but assemblage A is consistently present at proportions ranging from 10% to 40% [18, 19].

Mixed Infections and Coinfections

Mixed assemblage infections (e.g., A + C, C + D) are documented in both dogs and cats, complicating genotyping efforts. Single-locus PCR may fail to detect mixed infections, whereas MLG or high-resolution melting (HRM) real-time PCR improves detection sensitivity [4, 20]. Coinfections with other enteric parasites, including Cryptosporidium spp., Cystoisospora spp., and Toxocara spp., are common and may influence clinical presentation [21, 22].

Clinical Signs and Pathogenesis

Pathophysiology

Trophozoite colonization of the duodenum and jejunum disrupts epithelial barrier function through multiple mechanisms. The ventral adhesive disc causes microvillous atrophy and effacement. Trophozoite-secreted proteases, including cysteine proteases, degrade tight junction proteins (claudin-1, occludin) and increase paracellular permeability. Apoptosis of enterocytes is induced via caspase-3 activation. The net effect is malabsorptive and secretory diarrhea, often accompanied by reduced disaccharidase activity and bile acid deconjugation [23, 24].

Clinical Presentation in Dogs

Clinical signs in dogs range from asymptomatic shedding to acute or chronic diarrhea. A study evaluating associations between assemblage type and clinical signs found that dogs infected with assemblage A were significantly more likely to exhibit diarrhea compared to those infected with assemblage C or D [25]. However, other studies have not consistently replicated this finding, suggesting that host factors (age, immune status, microbiome composition) and parasite load are important modifiers [23, 26]. Common clinical signs include:

• Soft to watery feces, often with mucus but rarely with frank blood
• Steatorrhea
• Flatulence and borborygmi
• Weight loss or poor growth in puppies
• Vomiting (less common)
• Lethargy and reduced appetite in severe cases

Clinical Presentation in Cats

Feline giardiasis is frequently subclinical, particularly in adult cats. Clinical disease is more common in kittens and immunocompromised individuals. Signs include:

• Acute or chronic small bowel diarrhea
• Mucus-laden feces
• Fecal incontinence
• Poor coat condition
• Weight loss

Assemblage F infections are often associated with milder clinical signs compared to assemblage A infections in cats [19, 17].

Diagnostic Approaches

Microscopic Detection

Fecal flotation using zinc sulfate (specific gravity 1.18-1.20) with centrifugation is the most sensitive conventional method for cyst detection. Cysts measure 8-14 micrometers in length and 7-10 micrometers in width. Direct saline smears and formalin-ethyl acetate concentration are less sensitive. Trophozoites may be identified in fresh, liquid feces or duodenal aspirates. Sensitivity of a single flotation is estimated at 60-70%, increasing to 90% with three samples collected over 48-72 hours [27, 22].

Antigen Detection

Commercial enzyme-linked immunosorbent assays (ELISAs) and immunochromatographic rapid tests detect cyst wall antigens (e.g., GSA-65) in feces. Sensitivity and specificity vary by manufacturer and test format. A comparative study of four diagnostic methods found that a commercial ELISA had sensitivity of 85.7% and specificity of 94.1% relative to PCR [27]. Antigen tests do not differentiate assemblages.

Molecular Detection and Genotyping

PCR Targets and Assay Design

Molecular diagnostics are essential for species confirmation and assemblage identification. The most commonly targeted loci include:

A commercial beta-giardin qPCR assay demonstrated high sensitivity and specificity for detection of zoonotic assemblages in cat and dog samples, with performance comparable to MLG [1]. This assay targets conserved regions of the bg gene and uses assemblage-specific probes to differentiate A, B, C, D, and F.

High-Resolution Melting (HRM) Real-Time PCR

HRM real-time PCR offers a closed-tube genotyping approach that eliminates the need for post-PCR sequencing. Following amplification of the bg or gdh locus, amplicons are subjected to a controlled denaturation gradient. Sequence variations produce distinct melting temperature (Tm) profiles that correspond to specific assemblages. This method can detect mixed infections and is effective regardless of parasite load [4, 20]. A study validating HRM for assemblages A and B reported 100% concordance with sequencing for samples with cyst loads as low as 10 cysts per gram of feces [4].

Multilocus Genotyping (MLG)

MLG involves sequencing at least two, and ideally three or more, independent loci. This approach is necessary to detect recombination events, mixed infections, and potential zoonotic transmission events. Discordant genotyping results between loci (e.g., bg identifies assemblage A while gdh identifies assemblage B) suggest mixed infections or genetic exchange [1, 28].

Diagnostic Workflow

flowchart TD
    A[Fecal sample collected], > B{Clinical suspicion?}
    B, >|Acute diarrhea| C[Zinc sulfate centrifugal flotation]
    B, >|Screening / chronic| D[Commercial ELISA or qPCR]
    C, > E{Positive?}
    E, >|No| F[Repeat flotation x2 over 48h]
    E, >|Yes| G[DNA extraction from feces]
    F, > H{Any positive?}
    H, >|No| I[Consider other etiologies]
    H, >|Yes| G
    G, > J[bg qPCR with assemblage probes]
    J, > K{Assemblage identified?}
    K, >|A or B| L[Report zoonotic genotype]
    K, >|C, D, or F| M[Report canid/felid genotype]
    K, >|Mixed / ambiguous| N[Perform MLG (bg + gdh + tpi)]
    N, > O[Confirm assemblage(s)]
    L, > P[Clinical management + zoonotic risk counseling]
    M, > P
    O, > P

Treatment and Clinical Management

Antiparasitic Agents

Fenbendazole

Fenbendazole is a benzimidazole anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. The standard protocol for dogs is 50 mg/kg orally once daily for 3 to 5 consecutive days. However, treatment failures have been documented. A study in naturally infected dogs in France reported a lack of efficacy of fenbendazole at 50 mg/kg for 3 days, with a fecal cure rate of only 33.3% [29]. Another study comparing fenbendazole and metronidazole over a 50-day monitoring period found that fenbendazole achieved parasitological cure in 60% of dogs, while metronidazole achieved 70% [30]. Resistance mechanisms may involve point mutations in the beta-tubulin gene, though this has not been definitively confirmed in G. duodenalis.

Metronidazole

Metronidazole is a nitroimidazole antibiotic that is reduced intracellularly to cytotoxic metabolites that damage DNA and inhibit nucleic acid synthesis. The recommended dose for dogs is 15-25 mg/kg orally twice daily for 5 to 7 days. For cats, 10-25 mg/kg orally twice daily for 5 to 7 days is used. Metronidazole is effective but associated with adverse effects including anorexia, vomiting, and neurotoxicity (ataxia, nystagmus) at higher doses or with prolonged use. A study comparing fenbendazole and metronidazole found no significant difference in efficacy, but metronidazole-treated dogs had a higher rate of adverse gastrointestinal effects [30].

Combination Therapy

For refractory cases, combination therapy with fenbendazole and metronidazole may be considered. Some clinicians also use secnidazole (a longer-acting nitroimidazole) or ronidazole, though these are not approved for this indication in many jurisdictions.

Environmental Control and Prevention

Reinfection is common in multi-animal households and shelter environments. Control measures include:

• Daily removal of feces from the environment
• Cleaning of contaminated surfaces with quaternary ammonium compounds or steam cleaning (cysts are inactivated at temperatures above 60 degrees Celsius)
• Bathing animals to remove cysts from the perineal fur
• Preventing access to contaminated water sources

Monitoring Treatment Response

Post-treatment fecal testing should be performed 7 to 14 days after completion of therapy. PCR-based testing is preferred over microscopy or antigen testing because it can detect low-level shedding and differentiate between treatment failure and reinfection. If clinical signs persist and the animal remains positive, genotyping should be repeated to assess for potential drug resistance or mixed infection [1, 27, 30].

Zoonotic Risk Assessment

Evidence for Zoonotic Transmission

The zoonotic potential of G. duodenalis from dogs and cats is a subject of ongoing investigation. Molecular evidence supports the transmission of assemblage A and, to a lesser extent, assemblage B between companion animals and humans. A study in northern Argentina provided evidence for cross-species transmission of assemblage A between humans and dogs based on identical multilocus genotypes [28]. In Bangladesh, assemblage A was detected in both dogs and cats, with subtypes identical to those found in local human clinical isolates [3]. A comprehensive risk assessment concluded that the risk of zoonotic transmission from dogs and cats is real but likely low in most settings, with the highest risk in households with immunocompromised individuals and young children [31, 18].

Assemblage-Specific Zoonotic Risk

• Assemblage A: Subtypes AI, AII, and AIII are all documented in humans and companion animals. AI is the most common subtype in dogs and cats and is frequently identified in human cases. This assemblage represents the highest zoonotic risk [1, 3, 14, 31].
• Assemblage B: Less commonly detected in dogs and cats than assemblage A. When present, it is often associated with human infection. Subtypes BIII and BIV are reported in both humans and animals [4, 6].
• Assemblages C, D, and F: These are considered host-adapted and are rarely, if ever, associated with human infection. However, assemblage F has been reported in humans in southern Brazil, suggesting that the host range may be broader than previously assumed [32].

Clinical Recommendations for Zoonotic Risk Management

Veterinarians should counsel owners of infected pets, particularly those with zoonotic assemblages, on basic hygiene measures: hand washing after handling feces, keeping the pet's living area clean, and avoiding fecal contamination of food preparation surfaces. Immunocompromised individuals should avoid direct contact with diarrheic feces. Routine screening of asymptomatic pets in households with immunocompromised members is not universally recommended but may be considered on a case-by-case basis [31, 18, 19].

Conclusions

Giardia duodenalis is a genetically diverse parasite with significant implications for companion animal health and potential zoonotic transmission. Accurate diagnosis requires molecular methods that can differentiate assemblages, as clinical management and zoonotic risk assessment depend on genotype. The predominance of canid-adapted assemblages C and D in dogs and felid-adapted assemblage F in cats underscores the importance of genotyping to avoid overestimation of zoonotic risk. Fenbendazole and metronidazole remain the primary therapeutic agents, but treatment failures are increasingly documented, necessitating post-treatment monitoring and, in refractory cases, combination therapy or alternative agents. Continued surveillance using standardized MLG approaches is essential to track the emergence of zoonotic genotypes and drug resistance patterns.

References

[1] Scorza AV, Leutenegger CM, Lozoya C, et al. Comparison of multilocus genotyping and a commercial beta-giardin qPCR assay for detection of Giardia duodenalis zoonotic assemblages in cat and dog samples. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41952221/

[2] Bačić A, Kapo N, Omeragić J, et al. Occurrence and molecular characterization of Giardia duodenalis in domestic and wild mesocarnivores in Bosnia and Herzegovina. Int J Parasitol Parasites Wildl. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41630860/

[3] Nahar A, Hasan MF, Harun AB, et al. Molecular detection and zoonotic potential of Cryptosporidium spp. and Giardia duodenalis in cats and dogs from metropolitan areas of Bangladesh. Food Waterborne Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41552711/

[4] Pinto-Gonçalves M, Ferreira BIDS, Da-Cruz AM, et al. High resolution melting real-time PCR for genotyping of Giardia lamblia assemblages A and B regardless of parasite load. Gut Pathog. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41331694/

[5] Jańczak D, Olszewski J, Maj AK, et al. Prevalence of Giardia duodenalis genetic assemblages isolated from dogs and cats in Poland. J Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41064408/

[6] Li SA, Lin YL, Bai YP, et al. Prevalence and molecular characterization of Cryptosporidium spp. and Giardia duodenalis in humans and dogs from Fujian Province, Southeast China. Food Waterborne Parasitol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40761888/

[7] Zhao ZY, Li MH, Lyu C, et al. Prevalence of Giardia duodenalis Among Dogs in China from 2001 to 2021: A Systematic Review and Meta-Analysis. Foodborne Pathog Dis. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35020482/

[8] Yun CS, Moon BY, Lee K, et al. Prevalence and genotype analysis of Cryptosporidium and Giardia duodenalis from shelter dogs in South Korea. Vet Parasitol Reg Stud Reports. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39326959/

[9] Çelik BA, Çelik ÖY, Koçhan A, et al. Prevalence and genotypes of Giardia duodenalis in shelter dogs of southeastern Türkiye. Vet Res Forum. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38169512/

[10] Hsu CH, Liang C, Chi SC, et al. An Epidemiological Assessment of Cryptosporidium and Giardia spp. Infection in Pet Animals from Taiwan. Animals (Basel). 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37958128/

[11] Mateo M, Montoya A, Bailo B, et al. Prevalence and public health relevance of enteric parasites in domestic dogs and cats in the region of Madrid (Spain) with an emphasis on Giardia duodenalis and Cryptosporidium sp. Vet Med Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37725371/

[12] Agresti A, Berrilli F, Maestrini M, et al. Prevalence, Risk Factors and Genotypes of Giardia duodenalis in Sheltered Dogs in Tuscany (Central Italy). Pathogens. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/35055960/

[13] Pereira A, Teixeira J, Sousa S, et al. Giardia duodenalis infection in dogs from the metropolitan area of Lisbon, Portugal: prevalence, genotyping and associated risk factors. J Parasit Dis. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34295036/

[14] Asghari A, Mohammadi MR, Motazedian MH, et al. Assessing the public health and zoonotic impacts of Giardia duodenalis assemblages in domestic animals of southwestern Iran. J Parasit Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39975619/

[15] Harvey TV, Carvalho JPDS, Aquino MCC, et al. Giardiasis in children and dogs, and the first report of assemblage E in dogs from northeastern Brazil. Rev Bras Parasitol Vet. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36820730/

[16] Fazaeli A, Kohansal MH, Spotin A, et al. Infection rate and genetic diversity of Giardia duodenalis assemblage C in Iranian stray dogs, targeting the glutamate dehydrogenase gene. Vet World. 2021. URL: https

[17] Elmahallawy EK, Gareh A, Abu-Okail A, et al. Molecular characteristics and zoonotic potential of enteric protists in domestic dogs and cats in Egypt. Front Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37483300/

[18] Barbosa AD, Egan S, Feng Y, et al. Cryptosporidium and Giardia in cats and dogs: What is the real zoonotic risk? Curr Res Parasitol Vector Borne Dis. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38089689/

[19] Kanski S, Weber K, Busch K. [Feline and canine giardiosis: An Update]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38056479/

[20] Bahramdoost Z, Mirjalali H, Yavari P, et al. Development of HRM real-time PCR for assemblage characterization of Giardia lamblia. Acta Trop. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34450062/

[21] Szydłowicz M, Zajączkowska Ż, Lewicka A, et al. Host-specific Cryptosporidium, Giardia and Enterocytozoon bieneusi in shelter dogs from central Europe. Parasitology. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38305092/

[22] Leutenegger CM, Lozoya CE, Tereski J, et al. Comparative study of a broad qPCR panel and centrifugal flotation for detection of gastrointestinal parasites in fecal samples from dogs and cats in the United States. Parasit Vectors. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37587483/

[23] Šmit I, Potočnjak D, Matijatko V, et al. The Influence of Giardia duodenalis on the Occurrence of Clinical Signs in Dogs. Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38133245/

[24] Argüello-García R, Ortega-Pierres MG. Giardia duodenalis Virulence - "To Be, or Not To Be". Curr Trop Med Rep. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34697581/

[25] Scorza AV, Buch J, Franco P, et al. Evaluation for associations amongst Giardia duodenalis assemblages and diarrhea in dogs. Vet Parasitol. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34735843/

[26] Sui Y, Zhang X, Wang H, et al. Prevalence and genetic diversity of Giardia duodenalis in pet dogs from Zhengzhou, central China and the association between gut microbiota and fecal characteristics during infection. One Health. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35686142/

[27] Gabrielli S, Milardi GL, Scarinci L, et al. Comparative performance evaluation of four different methods for diagnosing Giardia infection in dogs and zoonotic assemblages' identification. Vet Parasitol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38749124/

[28] Kuthyar S, Kowalewski MM, Seabolt M, et al. Molecular characterization of Giardia duodenalis and evidence for cross-species transmission in Northern Argentina. Transbound Emerg Dis. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34224652/

[29] Kaufmann H, Zenner L, Benabed S, et al. Lack of efficacy of fenbendazole against Giardia duodenalis in a naturally infected population of dogs in France. Parasite. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36315102/

[30] Ciuca L, Pepe P, Bosco A, et al. Effectiveness of Fenbendazole and Metronidazole Against Giardia Infection in Dogs Monitored for 50-Days in Home-Conditions. Front Vet Sci. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33842570/

[31] Sun J, Qin Z, Fu Y, et al. Assessment of potential zoonotic transmission of Giardia duodenalis from dogs and cats. One Health. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38116451/

[32] Silva ACDS, Martins FDC, Ladeia WA, et al. First report of Giardia duodenalis assemblage F in humans and dogs in southern Brazil. Comp Immunol Microbiol Infect Dis. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36108583/

[33] Hatam-Nahavandi K, Mohammad Rahimi H, Rezaeian M, et al. Detection and molecular characterization of Blastocystis sp., Enterocytozoon bieneusi and Giardia duodenalis in asymptomatic animals in southeastern Iran. Sci Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39979370/

[34] Kabir MHB, Kato K. Examining the molecular epidemiology of Giardia and Eimeria species in Japan: a comprehensive review. J Vet Med Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38556324/

[35] Idan SR, Al-Hasnawy MH. Microscopic and molecular diagnoses of Giardia duodenalis in pet animals in Babylon Province, Iraq. Vet World. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/38152260/

[36] Zhang J, Qin Y, Shen Y, et al. [Prevalence and genotyping of Cryptosporidium spp. and Giardia lamblia in dogs and cats from a pet hospital in Shanghai Municipality]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37455096/

[37] Cao Y, Fang C, Deng J, et al. Molecular characterization of Cryptosporidium spp. and Giardia duodenalis in pet dogs in Xinjiang, China. Parasitol Res. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35233676/

[38] Wang YG, Zou Y, Yu ZZ, et al. Molecular Investigation of Zoonotic Intestinal Protozoa in Pet Dogs and Cats in Yunnan Province, Southwestern China. Pathogens. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34578141/